Tumour lysis syndrome: an unexpected adverse event associated with ipilimumab.

Masson Regnault, M; Ofaiche, J; Boulinguez, S; Tournier, E; Rochaix, P; Paul, C; Lamant, L; Meyer, N

Masson Regnault, M; Ofaiche, J; Boulinguez, S; Tournier, E; Rochaix, P; Paul, C; Lamant, L; Meyer, N.

Affiliation

Masson Regnault M; Dermatology, Université Paul-Sabatier-Toulouse III and Institut Universitaire du Cancer de Toulouse, Toulouse, France.
Ofaiche J; Dermatology, Université Paul-Sabatier-Toulouse III and Institut Universitaire du Cancer de Toulouse, Toulouse, France.
Boulinguez S; Dermatology, Université Paul-Sabatier-Toulouse III and Institut Universitaire du Cancer de Toulouse, Toulouse, France.
Tournier E; Dermatology, Université Paul-Sabatier-Toulouse III and Institut Universitaire du Cancer de Toulouse, Toulouse, France.
Rochaix P; Pathology, Université Paul-Sabatier-Toulouse III and Institut Universitaire du Cancer de Toulouse, Toulouse, France.
Paul C; Dermatology, Université Paul-Sabatier-Toulouse III and Institut Universitaire du Cancer de Toulouse, Toulouse, France.
Lamant L; Pathology, Université Paul-Sabatier-Toulouse III and Institut Universitaire du Cancer de Toulouse, Toulouse, France.
Meyer N; INSERM UMR 1037-CRCT, Toulouse, France.

J Eur Acad Dermatol Venereol ; 31(2): e73-e74, 2017 Feb.

Article in En | MEDLINE | ID: mdl-27256718

Subject(s)

Antibodies, Monoclonal/adverse effects; Melanoma/etiology; Tumor Lysis Syndrome/etiology; Adult; Aged; Female; Humans; Ipilimumab; Male; Middle Aged

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tumor Lysis Syndrome / Melanoma / Antibodies, Monoclonal Type of study: Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Eur Acad Dermatol Venereol Year: 2017 Document type: Article

Fulltext

XML

PubMed Links

Search on Google